Navigation Links
Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings

Cambridge, Mass., and Worcester, Mass., March 1, 2012 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and the University of Massachusetts Medical School (UMMS) reported today that the European Patent Office (EPO) has upheld the Tuschl I '726 patent (EP 1309726) in oral opposition proceedings held in Munich, Germany. The requested claims of the '726 patent were upheld without any modification. Opponents included Sanofi-Aventis Deutschland GmbH, Silence Therapeutics AG, and BASF SE.

Inventors on the patent are David P. Bartel, PhD, a Howard Hughes Medical Institute Investigator and professor of biology at the Massachusetts Institute of Technology; Phillip A. Sharp, PhD, Institute Professor at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and a 1993 Nobel Laureate; Thomas Tuschl, PhD, a Howard Hughes Medical Institute Investigator and professor at Rockefeller University; and Phillip D. Zamore, PhD, a Howard Hughes Medical Institute Investigator and the Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Medical School, where he co-directs the RNA Therapeutics Institute.

"The Tuschl family of patents defines key discoveries central to the advancement of RNAi therapeutics to patients," said James P. McNamara, PhD, executive director, Office of Technology Management, University of Massachusetts Medical School. "The Tuschl I patent is a critical invention by Professors Tuschl, Zamore, Bartel, and Sharp regarding the RNAi mechanism. We are pleased to see this patent fully upheld in Europe in these opposition proceedings."

"We are very pleased with the outcome of these opposition proceedings which resulted in the claims from the Tuschl I '726 patent being fully upheld. This decision by the EPO affirms our belief in the validity of these claims, and the novelty of the Tuschl I invention, and supports the relevance of Tuschl I for the development and commercialization of RNAi therapeutics," said Laurence Reid, PhD, senior vice president and chief business officer of Alnylam. "Alnylam continues to leverage its leading patent estate for the advancement of innovative medicines to patients and also continues to enable the entire RNAi therapeutics field with over 30 license agreements formed to date."

"The research discoveries that form the basis for this patent were a significant milestone in the explication of the basic science of RNAi and the path to the world of RNA therapeutics," said Zamore. "The affirmation of the intellectual basis of these discoveries by the EPO will accelerate the opportunities for laboratories and research organizations around the world to use this science to work toward therapeutics to treat human disease."

Alnylam is the co-exclusive licensee of the Tuschl I '726 patent which is owned by the Max Planck Society, the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research, and the University of Massachusetts Medical School. This patent is a key component to Alnylam's fundamental intellectual property estate that comprises numerous issued or granted patents and a large number of pending patent applications that together broadly cover RNAi therapeutics, including small interfering RNAs, or siRNAs, the molecules that mediate RNAi. The Tuschl I '726 patent consists of 14 claims broadly covering RNAi methods, including methods of reducing the expression of a gene, with double stranded RNAs between 21 and 23 nucleotides in length of mammalian or viral origin. The patent also includes claims covering methods of examining the function of a gene, as well as the use of both unmodified and chemically modified double stranded RNAs.

About RNA Interference (RNAi)

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNAs (siRNAs), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.


Contact: Mark Shelton
University of Massachusetts Medical School

Related biology news :

1. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
2. UMass Medical School study points to genetic link in apnea of prematurity
3. UMASS Medical Schools human stem cell bank makes available first seven stem cell lines
4. UMass Amherst biologists use GPS to map bats teeth to explore evolutionary adaptations to diet
5. UMass med school professor wins coveted emerging-investigator award
6. UMass Amherst entomologists begin to control winter moth infestation in eastern Massachusetts
7. UMass researcher points to suppression of evidence on radiation effects by 1946 Nobel Laureate
8. UMass Amherst wins major grant to host $7.5 million Northeast Climate Science Center
9. UMass Amherst ecologists among the first to record and study deep-sea fish noises
10. Inspired by gecko feet, UMass Amherst scientists invent super-adhesive material
11. UMass Amherst chemical engineers say mini-cellulose molecule unlocks biofuel chemistry
Post Your Comments:
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
(Date:10/23/2015)... 2015 Research and Markets ( ) ... Recognition Biometrics Market 2015-2019" report to their offering. ... The global voice recognition biometrics market to grow at ... --> --> The report, Global ... on an in-depth market analysis with inputs from industry ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... in cat and human plaque and pave the way for ... health problems in cats     ... the most commonly diagnosed health problems in cats, yet relatively ... until now. Two collaborative studies have been conducted by researchers ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the ... other AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. ...
Breaking Biology Technology: